ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Faculty of 1000 evaluation for Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
F1000 - Post-publication peer review of the biomedical literature
◽
10.3410/f.718018463.793480272
◽
2013
◽
Author(s):
Sandra Nuyts
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Randomised Trial
◽
Open Label
◽
Phase 3
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Related Documents
Cited By
References
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
The Lancet Oncology
◽
10.1016/s1470-2045(13)70181-5
◽
2013
◽
Vol 14
(8)
◽
pp. 697-710
◽
Cited By ~ 301
Author(s):
Jan B Vermorken
◽
Jan Stöhlmacher-Williams
◽
Irina Davidenko
◽
Lisa Licitra
◽
Eric Winquist
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Randomised Trial
◽
Open Label
◽
Phase 3
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.718018463.793481234
◽
2013
◽
Author(s):
Bruce Brockstein
◽
Nicholas Campbell
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Randomised Trial
◽
Open Label
◽
Phase 3
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)
European Journal of Cancer
◽
10.1016/j.ejca.2019.08.018
◽
2019
◽
Vol 122
◽
pp. 53-60
◽
Cited By ~ 2
Author(s):
K. Klinghammer
◽
T. Gauler
◽
A. Dietz
◽
V. Grünwald
◽
J. Stöhlmacher
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Randomised Trial
◽
Open Label
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
The Lancet
◽
10.1016/s0140-6736(19)32591-7
◽
2019
◽
Vol 394
(10212)
◽
pp. 1915-1928
◽
Cited By ~ 230
Author(s):
Barbara Burtness
◽
Kevin J Harrington
◽
Richard Greil
◽
Denis Soulières
◽
Makoto Tahara
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Open Label
◽
Phase 3
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet
◽
10.1016/s0140-6736(18)31999-8
◽
2019
◽
Vol 393
(10167)
◽
pp. 156-167
◽
Cited By ~ 315
Author(s):
Ezra E W Cohen
◽
Denis Soulières
◽
Christophe Le Tourneau
◽
José Dinis
◽
Lisa Licitra
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Neck Squamous Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-18-1539
◽
2018
◽
Vol 25
(2)
◽
pp. 487-495
◽
Cited By ~ 4
Author(s):
Magnus T. Dillon
◽
Lorna Grove
◽
Kate L. Newbold
◽
Heather Shaw
◽
Nicholas F. Brown
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Open Label
◽
Phase Ib
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(11)70034-1
◽
2011
◽
Vol 12
(4)
◽
pp. 333-343
◽
Cited By ~ 165
Author(s):
Jean-Pascal Machiels
◽
Somasundaram Subramanian
◽
Agnes Ruzsa
◽
Gabor Repassy
◽
Igor Lifirenko
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Supportive Care
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Best Supportive Care
◽
Open Label
◽
Phase 3
◽
Platinum Based Chemotherapy
◽
Metastatic Squamous Cell Carcinoma
Download Full-text
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(15)70124-5
◽
2015
◽
Vol 16
(5)
◽
pp. 583-594
◽
Cited By ~ 239
Author(s):
Jean-Pascal H Machiels
◽
Robert I Haddad
◽
Jérôme Fayette
◽
Lisa F Licitra
◽
Makoto Tahara
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
Second Line
◽
Open Label
◽
Phase 3
◽
Metastatic Squamous Cell Carcinoma
◽
Head Neck
Download Full-text
A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651
Annals of Oncology
◽
10.1093/annonc/mdw376.68
◽
2016
◽
Vol 27
◽
pp. vi350
◽
Cited By ~ 5
Author(s):
A. Argiris
◽
M. Gillison
◽
R.L. Ferris
◽
K. Harrington
◽
T.K. Sanchez
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
First Line
◽
Open Label
◽
Phase 3
◽
First Line Therapy
◽
Line Therapy
◽
Metastatic Squamous Cell Carcinoma
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.736682352.793578124
◽
2020
◽
Author(s):
Jaffer Ajani
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Squamous Cell
◽
Oesophageal Squamous Cell Carcinoma
◽
Open Label
◽
Phase 3
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close